Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)‘s stock had its “hold” rating reissued by analysts at Janney Montgomery Scott in a note issued to investors on Wednesday. They presently have a $47.00 price objective on the specialty pharmaceutical company’s stock. Janney Montgomery Scott’s price target would indicate a potential upside of 23.52% from the company’s previous close.
A number of other research analysts have also issued reports on SUPN. Jefferies Group LLC reiterated a “buy” rating and issued a $51.00 price objective on shares of Supernus Pharmaceuticals in a report on Friday, August 4th. BidaskClub upgraded shares of Supernus Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, August 17th. Piper Jaffray Companies restated a “neutral” rating on shares of Supernus Pharmaceuticals in a report on Friday, August 4th. Stifel Nicolaus lowered shares of Supernus Pharmaceuticals from a “buy” rating to a “hold” rating and set a $47.00 price target for the company. in a report on Tuesday. They noted that the move was a valuation call. Finally, Cantor Fitzgerald restated a “buy” rating and set a $49.00 price target on shares of Supernus Pharmaceuticals in a report on Tuesday. Four analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $48.29.
Shares of Supernus Pharmaceuticals (SUPN) traded down 3.02% during midday trading on Wednesday, hitting $36.90. 1,504,976 shares of the stock traded hands. The firm’s 50-day moving average is $44.56 and its 200 day moving average is $37.95. The company has a market capitalization of $1.87 billion, a price-to-earnings ratio of 18.62 and a beta of 1.30. Supernus Pharmaceuticals has a 52 week low of $17.25 and a 52 week high of $50.05.
Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its quarterly earnings data on Wednesday, August 2nd. The specialty pharmaceutical company reported $0.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.24 by $0.08. The business had revenue of $75.83 million during the quarter, compared to analyst estimates of $68.54 million. Supernus Pharmaceuticals had a net margin of 41.10% and a return on equity of 30.73%. Equities analysts forecast that Supernus Pharmaceuticals will post $1.04 earnings per share for the current year.
In other Supernus Pharmaceuticals news, SVP Padmanabh P. Bhatt sold 5,000 shares of the firm’s stock in a transaction that occurred on Friday, September 8th. The shares were sold at an average price of $49.86, for a total transaction of $249,300.00. Following the completion of the transaction, the senior vice president now owns 12,500 shares in the company, valued at approximately $623,250. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, VP Padmanabh P. Bhatt sold 2,556 shares of the firm’s stock in a transaction that occurred on Friday, June 23rd. The stock was sold at an average price of $44.90, for a total transaction of $114,764.40. Following the sale, the vice president now directly owns 24,944 shares of the company’s stock, valued at approximately $1,119,985.60. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 160,000 shares of company stock valued at $7,505,574. Company insiders own 6.70% of the company’s stock.
Several hedge funds have recently made changes to their positions in SUPN. Meeder Asset Management Inc. grew its position in shares of Supernus Pharmaceuticals by 3,455.2% during the 2nd quarter. Meeder Asset Management Inc. now owns 2,382 shares of the specialty pharmaceutical company’s stock worth $103,000 after buying an additional 2,315 shares during the period. Ameritas Investment Partners Inc. acquired a new stake in shares of Supernus Pharmaceuticals during the 1st quarter worth approximately $127,000. Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of Supernus Pharmaceuticals by 278.2% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,018 shares of the specialty pharmaceutical company’s stock worth $130,000 after buying an additional 2,220 shares during the period. Riverhead Capital Management LLC grew its position in shares of Supernus Pharmaceuticals by 91.4% during the 2nd quarter. Riverhead Capital Management LLC now owns 3,062 shares of the specialty pharmaceutical company’s stock worth $132,000 after buying an additional 1,462 shares during the period. Finally, Advisor Group Inc. grew its position in shares of Supernus Pharmaceuticals by 13.7% during the 2nd quarter. Advisor Group Inc. now owns 3,395 shares of the specialty pharmaceutical company’s stock worth $145,000 after buying an additional 410 shares during the period. 95.38% of the stock is owned by institutional investors.
About Supernus Pharmaceuticals
Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.
Receive News & Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.